Possibility of age regulation of the natriuretic peptide C-receptor in human platelets

[1]  M. Yamauchi,et al.  The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Sagnella.  Measurement and significance of circulating natriuretic peptides in cardiovascular disease. , 1998, Clinical science.

[3]  H. Itoh,et al.  Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma. , 1998, Clinical chemistry.

[4]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[5]  J. Regnard,et al.  Characterization of human platelet receptors for atrial natriuretic peptide: evidence for clearance receptors. , 1996, Cellular and Molecular Biology.

[6]  F. Rengo,et al.  Effects of age on the role of atrial natriuretic factor in renal adaptation to physiologic variations of dietary salt intake. , 1996, Journal of the American Society of Nephrology : JASN.

[7]  J. Piletz,et al.  Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. , 1996, Journal of psychiatric research.

[8]  J. de Champlain,et al.  C‐type natriuretic peptide and brain natriuretic peptide inhibit adenylyl cyclase activity: interaction with ANF‐R2/ANP‐C receptors , 1995, FEBS letters.

[9]  R. Ziegler,et al.  C-type natriuretic peptide neuromodulates via "clearance" receptors. , 1995, The American journal of physiology.

[10]  G. Gauquelin,et al.  Transient downregulation of glomerular atrial natriuretic factor receptors in high output heart failure in the rat. , 1995, Cardiovascular Research.

[11]  D. Schocken,et al.  Three Peptides From the Atrial Natriuretic Factor Prohormone Amino Terminus Lower Blood Pressure and Produce Diuresis, Natriuresis, and/or Kaliuresis in Humans , 1994, Circulation.

[12]  D. Gardner.  Molecular biology of the natriuretic peptides. , 1994, Trends in cardiovascular medicine.

[13]  J. Regnard,et al.  Atrial natriuretic factor receptors on human platelets. , 1994, Cellular and Molecular Biology.

[14]  R. Giorgino,et al.  Reduced effectiveness of atrial natriuretic factor in pre-menopausal obese women. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[15]  M. Anand-Srivastava,et al.  Atrial natriuretic factor receptors and signal transduction mechanisms. , 1993, Pharmacological reviews.

[16]  L. Campbell,et al.  The platelet angiotensin II receptor in type I diabetes: studies in patients with and without nephropathy , 1993, European journal of clinical investigation.

[17]  M. Anand-Srivastava.  Differential regulation of ANF-R2 receptors coupled to adenylyl cyclase in cardiovascular tissues in hypertension. , 1993, American journal of hypertension.

[18]  E. Levin,et al.  Natriuretic peptide C-receptor: more than a clearance receptor. , 1993, The American journal of physiology.

[19]  H. Ruskoaho.  Atrial natriuretic peptide: synthesis, release, and metabolism. , 1992, Pharmacological reviews.

[20]  M. Brown,et al.  Natriuretic peptide receptor mRNAs in the rat and human heart. , 1992, The Journal of clinical investigation.

[21]  B. Myers,et al.  Regulation of platelet clearance receptors for atrial natriuretic peptide in diabetic nephropathy. , 1992, Journal of the American Society of Nephrology : JASN.

[22]  M. Currie,et al.  Inhibition of endothelial cell clearance of atrial natriuretic peptide by cyclic GMP treatment. , 1992, Biochemical and biophysical research communications.

[23]  S. Lightman,et al.  Plasma atrial natriuretic peptide concentration and platelet atrial natriuretic peptide binding site density in ageing and hypertension. , 1991, Clinical science.

[24]  M. Cantin,et al.  The presence of atrial-natriuretic-factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction system. , 1991, The Biochemical journal.

[25]  M. Currie,et al.  Cyclic GMP down-regulates atrial natriuretic peptide receptors on cultured vascular endothelial cells. , 1991, The Journal of biological chemistry.

[26]  J. Wei,et al.  Influence of age and dose on the end-organ responses to atrial natriuretic peptide in humans. , 1991, American journal of hypertension.

[27]  H. De León,et al.  Regulation of glomerular atrial natriuretic factor receptor subtypes by renal sympathetic nerves. , 1991, The American journal of physiology.

[28]  E. Schiffrin,et al.  Solubilization and molecular characterization of the atrial natriuretic peptide (ANP) receptor in human platelets: comparison with ANP receptors in rat tissues. , 1991, The Journal of clinical endocrinology and metabolism.

[29]  M. Cantin,et al.  Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. , 1990, The Journal of biological chemistry.

[30]  H. Motulsky,et al.  Calculating receptor number from binding experiments using same compound as radioligand and competitor. , 1989, Trends in pharmacological sciences.

[31]  T. Strom,et al.  Effects of a bolus dose of atrial natriuretic factor in young and elderly volunteers , 1989, European journal of clinical investigation.

[32]  F. Murad,et al.  Stimulatory effects of atrial natriuretic factor on phosphoinositide hydrolysis in cultured bovine aortic smooth muscle cells. , 1989, Biochimica et biophysica acta.

[33]  T. Strom,et al.  Binding sites for atrial natriuretic peptide on platelets in patients with congestive cardiomyopathy , 1988, European journal of clinical investigation.

[34]  E. Schiffrin,et al.  Platelet binding sites and plasma concentration of atrial natriuretic peptide in patients with essential hypertension. , 1988, Journal of hypertension.

[35]  E. Schiffrin,et al.  Decreased density of binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure. , 1988, Clinical science.

[36]  A. Kenny,et al.  The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. , 1987, The Biochemical journal.

[37]  E. Schiffrin,et al.  Platelet Binding Sites for Atrial Natriuretic Factor in Humans: Characterization and Effects of Sodium Intake , 1986, Hypertension.

[38]  E. Schiffrin,et al.  Cyclic GMP as mediator and biological marker of atrial natriuretic factor. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[39]  R. Cuneo,et al.  Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. , 1986, Life sciences.

[40]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.

[41]  H. Motulsky,et al.  Characterization of α2-adrenergic receptors on human platelets using [3H]yohimbine , 1980 .

[42]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[43]  C. Frampton,et al.  Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. , 1993, The Journal of clinical endocrinology and metabolism.

[44]  K. Hosoda,et al.  Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. , 1992, Endocrinology.